Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia
| Autor: | Ariel Winnick, Omar Viswanath, Cyrus Yazdi, Jonathan P. Eskander, Amnon A Berger, Alan D. Kaye, Joseph Keefe, Ivan Urits, Elasaf Gilbert |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Fibromyalgia media_common.quotation_subject Population Medical Marijuana law.invention Randomized controlled trial law Widespread Chronic Pain Milnacipran medicine Cannabidiol Humans Pain Management Intensive care medicine education Cannabis Randomized Controlled Trials as Topic media_common education.field_of_study biology business.industry Addiction Chronic pain medicine.disease biology.organism_classification Treatment Outcome Anesthesiology and Pain Medicine business medicine.drug |
| Zdroj: | Best Practice & Research Clinical Anaesthesiology. 34:617-631 |
| ISSN: | 1521-6896 |
| DOI: | 10.1016/j.bpa.2020.08.010 |
| Popis: | Fibromyalgia is a complex disease process that is as prevalent as it is poorly understood. Research into the pathophysiology is ongoing, and findings will likely assist in identifying new therapeutic options to augment those in existence today that are still insufficient for the care of a large population of patients. Recent evidence describes the use of cannabinoids in the treatment of fibromyalgia. This study provides a systematic, thorough review of the evidence alongside a review of the seminal data regarding the pathophysiology, diagnosis, and current treatment options. Fibromyalgia is characterized by widespread chronic pain, fatigue, and depressive episodes without an organic diagnosis, which may be prevalent in up to 10% of the population and carries a significant cost in healthcare utilization, morbidity, a reduced quality of life, and productivity. It is frequently associated with psychiatric comorbidities. The diagnosis is clinical and usually prolonged, and diagnostic criteria continue to evolve. Some therapies have been previously described, including neuropathic medications, milnacipran, and antidepressants. Despite some level of efficacy, only physical exercise has strong evidence to support it. Cannabis has been used historically to treat different pain conditions since ancient times. Recent advances allowed for the isolation of the active substances in cannabis and the production of cannabinoid products that are nearly devoid of psychoactive influence and provide pain relief and alleviation of other symptoms. Many of these, as well as cannabis itself, are approved for use in chronic pain conditions. Evidence supporting cannabis in chronic pain conditions is plentiful; however, in fibromyalgia, they are mostly limited. Only a handful of randomized trials exists, and their objectivity has been questioned. However, many retrospective trials and patient surveys suggest the significant alleviation of pain, improvement in sleep, and abatement of associated symptoms. Evidence supporting the use of cannabis in chronic pain and specifically in fibromyalgia is being gathered as the use of cannabis increases with current global trends. While the current evidence is still limited, emerging data do suggest a positive effect of cannabis in fibromyalgia. Cannabis use is not without risks, including psychiatric, cognitive, and developmental as well as the risks of addiction. As such, clinical judgment is warranted to weigh these risks and prescribe to patients who are more likely to benefit from this treatment. Further research is required to define appropriate patient selection and treatment regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|